The effect of angiotensin-converting enzyme inhibitors on plasma adipokine levels in normotensive patients with coronary artery disease

Endokrynologia Polska

Volumn 61, Issue 3, 2010, Pages 280-286

  Krysiak, Robert ^a   Sierant, Marian ^a   Marek, Bogdan ^a,b   Bienek, Radosław ^b   Okopień, Bogusław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b Third Provincial Hospital   (Poland)

Author keywords

Adiponectin; Angiotensin converting enzyme inhibitors; Arterial blood pressure; Coronary artery disease; Leptin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LEPTIN; PERINDOPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FEMALE; HUMAN; MALE; PROTEIN BLOOD LEVEL; SAMPLE; TREATMENT RESPONSE;

ADIPONECTIN; ADIPOSE TISSUE; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CORONARY DISEASE; ENALAPRIL; FEMALE; HUMANS; LEPTIN; MALE; MIDDLE AGED; PERINDOPRIL; RETROSPECTIVE STUDIES;

EID: 77955615615     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Dagenais GR, Pogue J, Fox K et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-558.
2. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788.
3. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
4. Campbell DJ. A review of perindopril in the reduction of cardiovascular events. Vasc Health Risk Manag 2006; 2: 117-124.
5. Sironi L, Nobili E, Gianella A et al. Anti-inflammatory properties of drugs acting on the renin-angiotensin system. Drugs Today 2005; 41: 609-622.
6. Neultel JM. Effect of the renin-angiotensin system on the vessel wall: using ACE inhibition to improve endothelial function. J Hum Hypertens 2004; 18: 599-606.
7. Kothari SA, Le MK, Gandhi PJ. Effects of angiotensin converting enzyme inhibitors on thrombotic mediators: potential clinical implications. J Thromb Thrombolysis 2003; 15: 217-225.
8. Naftilan AJ. Role of the tissue renin-angiotensin system in vascular remodeling and smooth muscle cell growth. Curr Opin Nephrol Hypertens 1994; 3: 218-227.
9. Koh KK, Quon MJ, Han SH et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010; 140: 73-81.
10. Masuo K, Mikami H, Ogihara T et al. Weight reduction and pharmacologic treatment in obese hypertensives. Am J Hypertens. 2001; 14: 530-538.
11. Mathai ML, Naik S, Sinclair AJ et al. Selective reduction in body fat mass and plasma leptin induced by angiotensin-converting enzyme inhibition in rats. Int J Obes (Lond) 2008; 32: 1576-1584.
12. Jayasooriya AP, Begg DP, Chen N et al. Omega-3 polyunsaturated fatty acid supplementation reduces hypertension in TGR(mRen-2)27 rats. Prostaglandins Leukot Essent Fatty Acids 2008; 78: 67-72.
13. Santos EL, de Picoli Souza K, da Silva ED et al. Long term treatment with ACE inhibitor enalapril decreases body weight gain and increases life span in rats. Biochem Pharmacol 2009; 78: 951-958.
14. Huang SS, Wu TC, Lin SJ et al. Combination of an ACE inhibitor and Indapamide improves blood pressure control, but attenuates the beneficial effects of ACE inhibition on plasma adiponectin in patients with essential hypertension. Circ J 2009; 73: 2282-2287.
15. Yenicesu M, Yilmaz MI, Caglar K et al. Blockade of the renin-angiotensin system increases plasma adiponectin levels in type-2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: c115-c121.
16. Yilmaz MI, Sonmez A, Caglar K et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-153.
17. Lely AT, Krikken JA, Bakker SJ et al. Low dietary sodium and exogenous angiotensin II infusion decrease plasma adiponectin concentrations in healthy men. J Clin Endocrinol Metab 2007; 92: 1821-1826.
18. Potenza MA, Marasciulo FL, Tarquinio M et al. Treatment of spontaneously hypertensive rats with rosiglitazone and/or enalapril restores balance between vasodilator and vasoconstrictor actions of insulin with simultaneous improvement in hypertension and insulin resistance. Diabetes 2006; 55: 3594-3603.
19. Amador N, Pérez-Luque E, Malacara JM et al. Leptin and heart sympathetic activity in normotensive obese and non-obese subjects. Ital Heart J 2004; 5: 29-35.
20. Ficek J, Kokot F, Chudek J et al. Influence of antihypertensive treatment with perindopril, pindolol or felodipinon plasma leptin concentration in patients with essential hypertension. Horm Metab Res 2002; 34: 703-708. (Pubitemid 36398711)
21. Piecha G, Adamczak M, Chudek J et al. Indapamide decreases plasma adiponectin concentration in patients with essential hypertension. Kidney Blood Press Res 2007; 30: 187-194. (Pubitemid 46976037)
22. Delles C, Raff U, Mimran A et al. Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008; 21: 1330-1336.
23. Krysiak R, Okopień B. Pleiotropic effects of angiotensin- converting enzyme inhibitors in normotensive patients with coronary artery disease. Pharmacol Rep 2008; 60: 514-523.
24. Krysiak R, Okopień B, Herman ZS. Adipose tissue: a new endocrine organ. Przegl Lek 2005; 62: 919-923.
25. Gualillo O, González-Juanatey JR, Lago F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspectives. Trends Cardiovasc Med 2007; 17: 275-283. (Pubitemid 350087698)
26. Pischon T, Girman CJ, Hotamisligil GS et al. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004; 291: 1730-1737. (Pubitemid 38489895)
27. Nakamura Y, Shimada K, Fukuda D et al. Implications of plasma concentrations of adiponectin in patients with coronary artery disease. Heart 2004; 90: 528-533.
28. Wallace AM, McMahon AD, Packard CJ et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104: 3052-3056.
29. Wolk R, Berger P, Lennon RJ et al. Plasma leptin and prognosis in patients with established coronary atherosclerosis. J Am Coll Cardiol 2004; 44: 1819-1824. (Pubitemid 39424081)
30. Krysiak R, Łabuzek K, Okopień B. Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep 2009; 61: 1134-1145.
31. Dzau VJ, Bernstein K, Celermajer D et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16: 149-160.
32. Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol 2005; 170: 407-442.
33. Tarquini R, Lazzeri C, Laffi G et al. Adiponectin and the cardiovascular system: from risk to disease. Intern Emerg Med 2007; 2: 165-176.
34. Ashwin PJ, Dilipbhai PJ. Leptin and the cardiovascular system: a review. Recent Patents Cardiovasc Drug Discov 2007; 2: 100-109.
35. Satoh M, Tabuchi T, Minami Y et al. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease. Clin Ther 2009; 31: 2113-2125.
36. Velkoska E, Warner FJ, Cole TJ et al. Metabolic effects of low dose angiotensin converting enzyme inhibitor in dietary obesity in the rat. Nutr Metab Cardiovasc Dis 2010; 20: 49-55.